Risk factors
Seres Therapeutics (MCRB) risk factors
Item 1A of every Seres Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors82 risks8 new14 reworded
Funding pressure remains central: Seres has $45.8 million cash, expects funding after Q3 2026, and discloses substantial going-concern doubt.
Filed Mar 12, 2026 - FY2024 10-K risk factors74 risks
Seres Therapeutics faces severe going concern doubts, requiring near-term funding while advancing its clinical pipeline.
Filed Mar 13, 2025